The role of hyaluronan degradation products as innate alloimmune agonists

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2622-2635

  Tesar, B M ^a   Jiang, D ^a   Liang, J ^a   Palmer, S M ^b   Noble, P W ^a   Goldstein, D R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dendritic cell; Toll like receptor

Indexed keywords

CHEMOKINE RECEPTOR CCR7; GLYCOSAMINOGLYCAN; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; DENDRITIC CELL; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCAN METABOLISM; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LUNG TRANSPLANTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; HYALURONIC ACID; INFLAMMATION; ISOANTIGENS; LUNG TRANSPLANTATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; OLIGOSACCHARIDES; SKIN TRANSPLANTATION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750024480     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01537.x     Document Type: Article

References (58)

1. Mellman I, Steinman RM. Dendritic cells: Specialized and regulated antigen processing machines. Cell 2001; 106: 255-258.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
3. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
4. O'Neill LAJ, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003; 24: 286-289.
5. Yamamoto M, Sato S, Hemmi H et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329.
6. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-333.
7. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls toll-like receptor signaling. Cell 2006; 125: 943.
8. Yamamoto M, Sato S, Hemmi H et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643.
9. Hoebe K, Du X, Georgel P et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424: 743-748.
10. Hoebe K, Janssen EM, Kim SO et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 2003; 4: 1223-1229.
11. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145.
12. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4. J Immunol 2002; 168: 5233-5239.
13. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195: 99-111.
14. Shi Y, Evans J, Rock K. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
15. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. J Biol Chem 2002; 277: 15107-15112.
16. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-561.
17. Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol 2005; 175: 2777-2782.
18. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves toll-like receptor 4. J Immunol 2002; 168: 5989-5992.
19. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation - friend or foe? Immunity 2001; 14: 357-368.
20. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571-1578.
21. Tesar BM, Zhang J, Li Q, Goldstein DR. TH1 immune responses to fully mhc mismatched allografts are diminished in the absence of myd88, a toll like receptor signal adaptor protein. Am J Transplant 2004; 4: 1429-1439.
22. Wells A, Larsson E, Hanas E, Laurent T, Hallgren R, Tufveson G. Increased hyaluronan in acutely rejecting human kidney grafts. Transplantation 1993; 55: 1346-1349.
23. Hallgren R, Gerdin B, Tufverson T. Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. J Exp Med 1990; 171: 2063-2076.
24. Qian J, Moliterno R, Donovan-Peluso MA et al. Expression of stress proteins and lymphocyte reactivity in heterotopic cardiac allografts undergoing cellular rejection. Transpl Immunol 1995; 3: 114-123.
25. Birk OS, Gur SL, Elias D et al. The 60-kDa heat shock protein modulates allograft rejection. Proc Natl Acad Sci U S A 1999; 96: 5159-5163.
26. Luo Y, Preswitch GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999; 103: 755-756.
27. Tesar BM, Chalasani G, Smith-Diggs L, Baddoura FK, Lakkis FG, Goldstein DR. Direct antigen presentation by a xenograft induces immunity independently of secondary lymphoid organs. J Immunol 2004; 173: 4377-4386.
28. Lau CL, Palmer SM, D'Amico TA, Tapson VF, Davis RD. Lung transplantation at Duke University Medical Center. Clin Transpl 1998: 327-340..
29. Cooper JDBM, Egan T, Hertz MI et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713-716.
30. Teder P, Vandivier RW, Jiang D et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-158.
31. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14: 129-135.
32. Jiang D, Liang J, Fan J et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-1179.
33. Palmer SM, Burch LH, Davis RD et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168: 628-632.
34. Lu L, Thomson AW. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002; 73 (1 Suppl): S19-S22.
35. Lechler R, Sykes M, Thomson A, Turka L. Organ transplantation - how much of the promise has been realized? Nat Med 2005; 11: 605-613.
36. Heeger PS, Lalli PN, Lin F et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530.
37. Dallman MJ, Smith E, Benson RA, Lamb JR. Notch: Control of lymphocyte differentiation in the periphery. Curr Opin Immunol 2005; 17: 259.
38. Knoflach A, Magee C, Denton MD et al. Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Transplantation 1999; 67: 909-914.
39. Pockley AG. Heat shock proteins, anti-heat shock protein reactivity and allograft rejection. Transplantation 2001; 71: 1503-1507.
40. Rizzo M, Alevy YG, Sundaresan S et al. Increased expression of HDJ-2 (heat shock protein 40) and heat shock protein 70 in biopsy specimens of transplanted human lungs. J Heart Lung Transplant 1998; 17: 241-249.
41. Mehta NK, Carroll M, Sykes DE et al. Heat shock protein 70 expression in native and heterotopically transplanted rat hearts. J Surg Res 1997; 70: 151-155.
42. Zhang W, Gao L, Qi S et al. Blocking of CD44-hyaluronic acid interaction prolongs rat allograft survival. Transplantation 2000; 27: 665-667.
43. Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 2005; 26 (3): 231-246.
44. Do Y, Nagarkatti PS, Nagarkatti M. Role of CD44 and hyaluronic acid (HA) in activation of alloreactive and antigen-specific T cells by bone marrow-derived dendritic cells. J Immunother 2004; 27: 1-12.
45. Hampton CR, Shimamoto A, Rothnie CL et al. HSP70.1 and 70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. Am J Physiol Heart Circ Physiol 2003; 285: H866-H874.
46. Kodaira Y, Nair SK, Wrenshall LE, Gilboa E, Platt JL. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol 2000; 165: 1599-1604.
47. Termeer CC, Hennies J, Voith U et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165 (4): 1863-1870.
48. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996; 183: 2373-2378.
49. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-776.
50. Bingaman AW, Ha J, Waitze S-Y et al. Vigorous allograft rejection in the absence of danger. J Immunol 2000; 164: 3065-3071.
51. Chalasani G, Li Q, Konieczny BT et al. The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response. J Immunol 2004; 172: 7813-7820.
52. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections. Am J Med 1974; 56: 280-289.
53. Finkelstein FO, Bastl C, Schiff M, Siegel NJ. Listeria sepsis immediately preceding renal transplant rejection. JAMA 1976; 235: 844-845.
54. Gabriel R, Selwyn S, Brown D et al. Virus infections and acute renal transplant rejection. Nephron 1976; 16: 282-286.
55. Smith C, Pilgrim H, Steinmuller D. The survival of skin allografts and xenografts in germ-free mice. Transplantation 1972; 13: 38-41.
56. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652-658.
57. Zhai Y, Shen X-D, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via ifn regulatory factor 3-dependent myd88-independent pathway. J Immunol 2004; 173: 7115-7119.
58. Yamamoto M, Sato S, Hemmi H et al. TRAM is specifically involved in the toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4: 1144-1150.